These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14586401)

  • 1. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.
    Turner SD; Tooze R; Maclennan K; Alexander DR
    Oncogene; 2003 Oct; 22(49):7750-61. PubMed ID: 14586401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas.
    Jäger R; Hahne J; Jacob A; Egert A; Schenkel J; Wernert N; Schorle H; Wellmann A
    Anticancer Res; 2005; 25(5):3191-6. PubMed ID: 16101126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy.
    Turner SD; Merz H; Yeung D; Alexander DR
    Anticancer Res; 2006; 26(5A):3275-9. PubMed ID: 17094440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
    Hsu FY; Johnston PB; Burke KA; Zhao Y
    Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.
    Lange K; Uckert W; Blankenstein T; Nadrowitz R; Bittner C; Renauld JC; van Snick J; Feller AC; Merz H
    Oncogene; 2003 Jan; 22(4):517-27. PubMed ID: 12555065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice].
    Merz H; Lange K; Nadrowitz R; Uckert W; Blankenstein T; Feller AC
    Verh Dtsch Ges Pathol; 2003; 87():224-31. PubMed ID: 16888916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
    Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
    Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas.
    Colomba A; Courilleau D; Ramel D; Billadeau DD; Espinos E; Delsol G; Payrastre B; Gaits-Iacovoni F
    Oncogene; 2008 Apr; 27(19):2728-36. PubMed ID: 17998938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
    Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
    Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T
    Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model.
    Miething C; Grundler R; Fend F; Hoepfl J; Mugler C; von Schilling C; Morris SW; Peschel C; Duyster J
    Oncogene; 2003 Jul; 22(30):4642-7. PubMed ID: 12879008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical screening for oncogenic tyrosine kinase activation.
    Pulford K; Delsol G; Roncador G; Biddolph S; Jones M; Mason DY
    J Pathol; 1999 Apr; 187(5):588-93. PubMed ID: 10398126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma.
    Watanabe M; Sasaki M; Itoh K; Higashihara M; Umezawa K; Kadin ME; Abraham LJ; Watanabe T; Horie R
    Cancer Res; 2005 Sep; 65(17):7628-34. PubMed ID: 16140928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential.
    Wang P; Wu F; Zhang J; McMullen T; Young LC; Ingham RJ; Li L; Lai R
    Carcinogenesis; 2011 Feb; 32(2):146-53. PubMed ID: 21045017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.
    Trinei M; Lanfrancone L; Campo E; Pulford K; Mason DY; Pelicci PG; Falini B
    Cancer Res; 2000 Feb; 60(4):793-8. PubMed ID: 10706082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.
    Hsu FY; Zhao Y; Anderson WF; Johnston PB
    Cancer Invest; 2007 Jun; 25(4):240-8. PubMed ID: 17612934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.
    Chikamori M; Fujimoto J; Tokai-Nishizumi N; Yamamoto T
    Oncogene; 2007 May; 26(20):2950-4. PubMed ID: 17086210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.
    Chiarle R; Simmons WJ; Cai H; Dhall G; Zamo A; Raz R; Karras JG; Levy DE; Inghirami G
    Nat Med; 2005 Jun; 11(6):623-9. PubMed ID: 15895073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
    Turturro F; Arnold MD; Frist AY; Pulford K
    Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma.
    Sjostrom C; Seiler C; Crockett DK; Tripp SR; Elenitoba Johnson KS; Lim MS
    Exp Hematol; 2007 Aug; 35(8):1240-8. PubMed ID: 17560012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.